TRANDOLAPRIL

Post-LOESM

trandolapril

Gen Pharmaceuticals

ANDAORALTABLET

Approved

Jun 2007

Lifecycle

Post-LOE

Competitive Pressure

30/100

Clinical Trials

Data completeness

5/8 — Partial

TRANDOLAPRIL (trandolapril) by Gen Pharmaceuticals is angiotensin-converting enzyme inhibitors [moa]. Approved for angiotensin converting enzyme inhibitor [epc]. First approved in 2007.

Drug data last refreshed 20h ago

$0.0BPart D

Mechanism of Action

Angiotensin-converting Enzyme Inhibitors

Indications

Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.

Clinical Trials (7)

NCT01078584N/ACompleted

Canadian Study of Trandolapril on Blood Pressure in Hypertensive Patients

Started Dec 2008

7,993 enrolled

Hypertension

NCT01164800Phase 1Completed

Bioequivalence Study of Trandolapril 4 mg Tablets of Dr. Reddy's Under Fed Conditions

Started Mar 2006

52 enrolled

Healthy

NCT01164787Phase 1Completed

Bioequivalence Study of Trandolapril 4 mg Tablets of Dr. Reddy's Under Fasting Conditions

Started Mar 2006

52 enrolled

Healthy

NCT00840632Phase 1Completed

Trandolapril 4 mg Tablet Under Fasting Conditions

Started Oct 2004

40 enrolled

Healthy

NCT00840073Phase 1Completed

Trandolapril 4 mg Tablet Under Non-Fasting Conditions

Started Oct 2004

50 enrolled

Healthy

Worked on TRANDOLAPRIL at Gen Pharmaceuticals? Share your interview experience or compensation data (+7 days Pro)

Data Sources

Drug label: DailyMed / FDA
Clinical trials: ClinicalTrials.gov
Patent data: FDA Orange Book
Spending data: CMS Medicare

The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.